Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Allogene TherapeuticsALLO +1.74%32 Market Cap is $705.84 Mil as of Aug. 10, 2026. GuruFocus rates ALLO with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,419 Biotechnology companies, Allogene Therapeutics ranks better than 75.12% on this metric.
Allogene Therapeutics's quarterly market cap
increased
from Sep. 2025 ($276.72 Mil) to Dec. 2025 ($314.30 Mil) and
increased
from Dec. 2025 ($314.30 Mil) to Mar. 2026 ($597.35 Mil).
Allogene Therapeutics's annual market cap
declined
from Dec. 2023 ($541.34 Mil) to Dec. 2024 ($452.01 Mil) and
declined
from Dec. 2024 ($452.01 Mil) to Dec. 2025 ($314.30 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Allogene Therapeutics's Enterprise Value for Today is $511.59 Mil.
Allogene Therapeutics (NAS:ALLO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Allogene Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allogene Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Allogene Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Allogene Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Allogene Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allogene Therapeutics (ALLO) has a Market Cap of $705.84 Mil as of Aug. 10, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Allogene Therapeutics and its competitors. According to the industry distribution chart, Allogene Therapeutics ranks #353 out of 1419 companies in the Biotechnology industry, placing it in the top 24.9%.
Is Allogene Therapeutics' Market Cap too high?
Allogene Therapeutics' current Market Cap is $705.84 Mil. The Biotechnology industry median Market Cap is 116.54. Allogene Therapeutics' value of $705.84 Mil is 505.7% above this industry median. Based on the distribution chart, Allogene Therapeutics ranks #353 out of 1419 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Allogene Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Allogene Therapeutics' Market Cap compare to CBIO and IMMX?
According to the Biotechnology industry distribution chart, Allogene Therapeutics ranks #353 out of 1419 companies for Market Cap. This places Allogene Therapeutics in the top 25% of its industry — outperforming the majority of peers. The industry median Market Cap is 116.54. Allogene Therapeutics' value of $705.84 Mil is 505.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 116.54, based on 1,419 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Allogene Therapeutics's current Market Cap of $705.84 Mil is 505.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Allogene Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 116.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allogene Therapeutics's current Market Cap is $705.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allogene Therapeutics stock overvalued right now?
Allogene Therapeutics (ALLO) has a current Market Cap of $705.84 Mil. The current Market Cap is $705.84 Mil and 505.7% above the Biotechnology industry median of 116.54. Allogene Therapeutics' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Allogene Therapeutics (ALLO), the current Market Cap is $705.84 Mil as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
32GF Score
Get the complete analysis for ALLO
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALLO has been successfully added to your 
